@article{ref1,
title="Health-related quality of life in patients treated with atypical antipsychotics",
journal="Revista brasileira de psiquiatria",
year="2020",
author="de Almeida, Juliana L. and Zuppo, Isabella de Figueiredo and Castel, Saulo and Reis, Edna A. and de Oliveira, Helian N. and Ruas, Cristina M.",
volume="42",
number="6",
pages="599-607",
abstract="OBJECTIVE: To assess health-related quality of life and associated factors in patients treated with atypical antipsychotics, as well as to determine utility values using the EuroQol-5D-3L instrument. <br><br>METHODS: A cross-sectional study was conducted at a state-run pharmacy in the Brazilian National Health System. Individuals were included if they were using a single atypical antipsychotic and completed the EuroQol-5D-3L. Sociodemographic, behavioral, and clinical data were collected. The dependent variable was the EuroQol-5D-3L utility score. Associations between the independent variables and the dependent variable were analyzed in a multiple linear regression model. <br><br>RESULTS: A total of 394 patients were included, and their mean utility score was 0.664±0.232. Patients treated with clozapine had the highest mean score (0.762 [0.202]), followed by olanzapine (0.687 [0.230]), risperidone (0.630 [0.252]), ziprasidone (0.622 [0.234]), and quetiapine (0.620 [0.243]). The following variables were related to higher utility scores: income, employment, clozapine use, no illicit psychoactive substance use, no suicide attempts, and no comorbidities. <br><br>CONCLUSION: Evaluating health-related quality of life differences in the available atypical antipsychotics can facilitate the choice of treatment, improve health outcomes, and ensure rational prescriptions.<p /><p>Language: en</p>",
language="en",
issn="1516-4446",
doi="10.1590/1516-4446-2019-0739",
url="http://dx.doi.org/10.1590/1516-4446-2019-0739"
}